Ivabradina Bluesar

Ivabradine, the active ingredient in Ivabradina Bluesar, is an If channel inhibitor presented as a tablet for oral use. It reduces heart rate and is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in adults. The product is manufactured under EU GMP guidelines and is available for export to multiple regions. GNH USA supplies Ivabradina Bluesar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements for safe distribution.

Ivabradine is used to manage conditions related to myocardial oxygen demand and heart rate control. Chronic stable angina pectoris: reduces frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers heart rate, improves symptoms and may reduce hospitalisation. Ischemic heart disease: helps relieve angina symptoms as part of comprehensive therapy.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Visual disturbances (phosphenes) especially at the start of treatment. - Bradycardia (resting heart rate <60 bpm). - Headache. - Dizziness. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Severe bradycardia leading to syncope. - Atrial fibrillation. - Symptomatic hypotension. - Persistent visual impairment. - Elevated liver enzymes. - Symptomatic heart block.

Before prescribing ivabradine, consider the following precautions. - Monitor heart rate: avoid use if resting HR is below 60 bpm. - Assess hepatic function: use with caution in severe impairment. - Evaluate for sick sinus syndrome or atrioventricular block: contraindicated. - Review concomitant beta‑blocker therapy to prevent excessive bradycardia. - Pregnancy and lactation: safety unknown; use only if clearly needed. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Ivabradine may interact with several medicines; monitor accordingly.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce efficacy. - Other heart‑rate‑lowering agents (beta‑blockers, digoxin): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Verapamil or diltiazem: may raise ivabradine concentrations. - Antacids containing aluminium or magnesium: can decrease absorption. - Simvastatin: may increase risk of visual disturbances.